The Claim
A single intravenous dose of 50 mg or 150 mg of K1-70TM in adults with Graves' disease is associated with clinically significant reductions in exophthalmos measurements of 2–5 mm within 14 to 42 days, alongside improvements in patient-reported symptoms including photosensitivity, eye pain, and conjunctival redness.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with Graves' disease, a single intravenous injection of 50 mg or 150 mg of K1-70TM is associated with a measurable decrease in bulging eyes by 2–5 mm within two to six weeks, along with reduced eye pain, redness, and sensitivity to light.
See the scientific wording
A single intravenous dose of 50 mg or 150 mg of K1-70TM in adults with Graves' disease is associated with clinically significant reductions in exophthalmos measurements of 2–5 mm within 14 to 42 days, alongside improvements in patient-reported symptoms including photosensitivity, eye pain, and conjunctival redness.
A specific antibody binds to the TSH receptor in the thyroid and behind the eyes, stopping signals that cause the thyroid to make too much hormone and the tissues behind the eyes to swell. This reduces eye bulging and relieves pain, redness, and light sensitivity.
What the research says
1 studyA single shot of K1-70TM helped people with Graves' eye disease see less eye bulging and feel less eye pain and light sensitivity within a few weeks, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.